Review



smac-af  (SMAC Corp)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    SMAC Corp smac-af
    Summaries of studies explored demonstrating impact of risk factor modification on AF ablation outcomes .
    Smac Af, supplied by SMAC Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/smac-af/smac+af/pmc11951490-2-14-5
    Average 90 stars, based on 1 article reviews
    smac-af - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "The Influence of Risk Factor Modification on Atrial Fibrillation Outcomes and Their Impact on the Success of Catheter Ablation"

    Article Title: The Influence of Risk Factor Modification on Atrial Fibrillation Outcomes and Their Impact on the Success of Catheter Ablation

    Journal: Reviews in Cardiovascular Medicine

    doi: 10.31083/RCM27175

    Summaries of studies explored demonstrating impact of risk factor modification on AF ablation outcomes .
    Figure Legend Snippet: Summaries of studies explored demonstrating impact of risk factor modification on AF ablation outcomes .

    Techniques Used: Modification, Control

    Related Articles

    Control:

    Article Title: Risk-factor modification to prevent recurrent atrial fibrillation after catheter ablation.
    Article Snippet: SMAC-AF (Substrate Modifi cation with Aggressive Blood Pressure Control)11 is the only randomized controlled trial to date investigating the infl uence of preprocedural blood pressure control on arrhythmia recurrence risk.

    Article Title: European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on catheter and surgical ablation of atrial fibrillation.
    Article Snippet: In the SMAC-AF randomized trial, short-term aggressive blood pressure (BP) treatment (target systolic BP 120mmHg) for a median duration of 3.5 months before scheduled AF catheter ablation in patients with hypertension did not reduce arrhythmia recurrence following ablation as compared to standard BP treatment (target systolic BP < 140mmHg)438.

    Article Title: Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal
    Article Snippet: , SMAC-AF , Patients undergoing ablation for AF: Aggressive treatment group ( n = 88) Standard care ( n = 85) , Target systolic BP <120 mmHg , AF recurrence post-ablation Aggressive treatment group: 71% Standard care: 64% (HR 1.12; CI, 0.78–1.62).

    Article Title: The Influence of Risk Factor Modification on Atrial Fibrillation Outcomes and Their Impact on the Success of Catheter Ablation
    Article Snippet: Parkash et al ., 2017 (SMAC-AF) [ ] , AF patients (57% paroxysmal) , Aggressive BP treatment (target < 120 mmHg) vs. standard BP treatment (target < 140 mmHg) , At 12 months: recurrence of AF/atrial tachycardia/atrial flutter not different to control group ( p = 0.763).

    Article Title: Risk-factor modification to prevent recurrent atrial fibrillation after catheter ablation.
    Article Snippet: Parkash R, Wells GA, Sapp JL, et al. Effect of aggressive blood pressure control on the recurrence of atrial fi brillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modifi cation with Aggressive Blood Pressure Control]).

    Article Title: Integrated Management of Persistent Atrial Fibrillation.
    Article Snippet: The 2017 SMAC-AF (Substrate Modification with Aggressive Blood Pressure Control) trial randomized patients into two groups: one with aggressive blood pressure control (<120/80 mm Hg) and another with standard control (<140/90 mm Hg).

    Article Title: Controversies in Hypertension II: The Optimal Target Blood Pressure.
    Article Snippet: Controversies in Hypertension II: The Optimal Target Blood Pressure Edward J. Filippone, MD, Andrew J. Foy, MD, Gerald V. Naccarelli, MD Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Department of Medicine, Penn State University Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center and College of Medicine, Hershey, Penn.

    Article Title: The Role of Risk Factor Modification in Atrial Fibrillation: Outcomes in Catheter Ablation
    Article Snippet: SMAC-AF , 2017 , 184 , 14 , Randomised open-label trial , 57% , Participants assigned to aggressive BP target (<120/80) or standard BP (<140/90) prior to ablation. Primary outcome was >30 s of AF/AT/AFL occurrence , There was no significant difference between the groups (61.4% of aggressive BP control vs. 61.2% in standard treatment group) p = 0.763 [ ] .

    Modification:

    Article Title: Risk-factor modification to prevent recurrent atrial fibrillation after catheter ablation.
    Article Snippet: SMAC-AF (Substrate Modifi cation with Aggressive Blood Pressure Control)11 is the only randomized controlled trial to date investigating the infl uence of preprocedural blood pressure control on arrhythmia recurrence risk.

    Article Title: European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on catheter and surgical ablation of atrial fibrillation.
    Article Snippet: In the SMAC-AF randomized trial, short-term aggressive blood pressure (BP) treatment (target systolic BP 120mmHg) for a median duration of 3.5 months before scheduled AF catheter ablation in patients with hypertension did not reduce arrhythmia recurrence following ablation as compared to standard BP treatment (target systolic BP < 140mmHg)438.

    Article Title: Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal
    Article Snippet: , SMAC-AF , Patients undergoing ablation for AF: Aggressive treatment group ( n = 88) Standard care ( n = 85) , Target systolic BP <120 mmHg , AF recurrence post-ablation Aggressive treatment group: 71% Standard care: 64% (HR 1.12; CI, 0.78–1.62).

    Article Title: The Influence of Risk Factor Modification on Atrial Fibrillation Outcomes and Their Impact on the Success of Catheter Ablation
    Article Snippet: Parkash et al ., 2017 (SMAC-AF) [ ] , AF patients (57% paroxysmal) , Aggressive BP treatment (target < 120 mmHg) vs. standard BP treatment (target < 140 mmHg) , At 12 months: recurrence of AF/atrial tachycardia/atrial flutter not different to control group ( p = 0.763).

    Article Title: Risk-factor modification to prevent recurrent atrial fibrillation after catheter ablation.
    Article Snippet: Parkash R, Wells GA, Sapp JL, et al. Effect of aggressive blood pressure control on the recurrence of atrial fi brillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modifi cation with Aggressive Blood Pressure Control]).

    Article Title: Integrated Management of Persistent Atrial Fibrillation.
    Article Snippet: The 2017 SMAC-AF (Substrate Modification with Aggressive Blood Pressure Control) trial randomized patients into two groups: one with aggressive blood pressure control (<120/80 mm Hg) and another with standard control (<140/90 mm Hg).

    Article Title: Controversies in Hypertension II: The Optimal Target Blood Pressure.
    Article Snippet: Controversies in Hypertension II: The Optimal Target Blood Pressure Edward J. Filippone, MD, Andrew J. Foy, MD, Gerald V. Naccarelli, MD Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Department of Medicine, Penn State University Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center and College of Medicine, Hershey, Penn.

    Article Title: The Role of Risk Factor Modification in Atrial Fibrillation: Outcomes in Catheter Ablation
    Article Snippet: SMAC-AF , 2017 , 184 , 14 , Randomised open-label trial , 57% , Participants assigned to aggressive BP target (<120/80) or standard BP (<140/90) prior to ablation. Primary outcome was >30 s of AF/AT/AFL occurrence , There was no significant difference between the groups (61.4% of aggressive BP control vs. 61.2% in standard treatment group) p = 0.763 [ ] .

    Activity Assay:

    Article Title: Risk-factor modification to prevent recurrent atrial fibrillation after catheter ablation.
    Article Snippet: SMAC-AF (Substrate Modifi cation with Aggressive Blood Pressure Control)11 is the only randomized controlled trial to date investigating the infl uence of preprocedural blood pressure control on arrhythmia recurrence risk.

    Article Title: European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on catheter and surgical ablation of atrial fibrillation.
    Article Snippet: In the SMAC-AF randomized trial, short-term aggressive blood pressure (BP) treatment (target systolic BP 120mmHg) for a median duration of 3.5 months before scheduled AF catheter ablation in patients with hypertension did not reduce arrhythmia recurrence following ablation as compared to standard BP treatment (target systolic BP < 140mmHg)438.

    Article Title: Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal
    Article Snippet: , SMAC-AF , Patients undergoing ablation for AF: Aggressive treatment group ( n = 88) Standard care ( n = 85) , Target systolic BP <120 mmHg , AF recurrence post-ablation Aggressive treatment group: 71% Standard care: 64% (HR 1.12; CI, 0.78–1.62).

    Article Title: The Influence of Risk Factor Modification on Atrial Fibrillation Outcomes and Their Impact on the Success of Catheter Ablation
    Article Snippet: Parkash et al ., 2017 (SMAC-AF) [ ] , AF patients (57% paroxysmal) , Aggressive BP treatment (target < 120 mmHg) vs. standard BP treatment (target < 140 mmHg) , At 12 months: recurrence of AF/atrial tachycardia/atrial flutter not different to control group ( p = 0.763).

    Article Title: Risk-factor modification to prevent recurrent atrial fibrillation after catheter ablation.
    Article Snippet: Parkash R, Wells GA, Sapp JL, et al. Effect of aggressive blood pressure control on the recurrence of atrial fi brillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modifi cation with Aggressive Blood Pressure Control]).

    Article Title: Integrated Management of Persistent Atrial Fibrillation.
    Article Snippet: The 2017 SMAC-AF (Substrate Modification with Aggressive Blood Pressure Control) trial randomized patients into two groups: one with aggressive blood pressure control (<120/80 mm Hg) and another with standard control (<140/90 mm Hg).

    Article Title: Controversies in Hypertension II: The Optimal Target Blood Pressure.
    Article Snippet: Controversies in Hypertension II: The Optimal Target Blood Pressure Edward J. Filippone, MD, Andrew J. Foy, MD, Gerald V. Naccarelli, MD Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Department of Medicine, Penn State University Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center and College of Medicine, Hershey, Penn.

    Article Title: The Role of Risk Factor Modification in Atrial Fibrillation: Outcomes in Catheter Ablation
    Article Snippet: SMAC-AF , 2017 , 184 , 14 , Randomised open-label trial , 57% , Participants assigned to aggressive BP target (<120/80) or standard BP (<140/90) prior to ablation. Primary outcome was >30 s of AF/AT/AFL occurrence , There was no significant difference between the groups (61.4% of aggressive BP control vs. 61.2% in standard treatment group) p = 0.763 [ ] .

    Comparison:

    Article Title: Risk-factor modification to prevent recurrent atrial fibrillation after catheter ablation.
    Article Snippet: SMAC-AF (Substrate Modifi cation with Aggressive Blood Pressure Control)11 is the only randomized controlled trial to date investigating the infl uence of preprocedural blood pressure control on arrhythmia recurrence risk.

    Article Title: European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on catheter and surgical ablation of atrial fibrillation.
    Article Snippet: In the SMAC-AF randomized trial, short-term aggressive blood pressure (BP) treatment (target systolic BP 120mmHg) for a median duration of 3.5 months before scheduled AF catheter ablation in patients with hypertension did not reduce arrhythmia recurrence following ablation as compared to standard BP treatment (target systolic BP < 140mmHg)438.

    Article Title: Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal
    Article Snippet: , SMAC-AF , Patients undergoing ablation for AF: Aggressive treatment group ( n = 88) Standard care ( n = 85) , Target systolic BP <120 mmHg , AF recurrence post-ablation Aggressive treatment group: 71% Standard care: 64% (HR 1.12; CI, 0.78–1.62).

    Article Title: The Influence of Risk Factor Modification on Atrial Fibrillation Outcomes and Their Impact on the Success of Catheter Ablation
    Article Snippet: Parkash et al ., 2017 (SMAC-AF) [ ] , AF patients (57% paroxysmal) , Aggressive BP treatment (target < 120 mmHg) vs. standard BP treatment (target < 140 mmHg) , At 12 months: recurrence of AF/atrial tachycardia/atrial flutter not different to control group ( p = 0.763).

    Article Title: Risk-factor modification to prevent recurrent atrial fibrillation after catheter ablation.
    Article Snippet: Parkash R, Wells GA, Sapp JL, et al. Effect of aggressive blood pressure control on the recurrence of atrial fi brillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modifi cation with Aggressive Blood Pressure Control]).

    Article Title: Integrated Management of Persistent Atrial Fibrillation.
    Article Snippet: The 2017 SMAC-AF (Substrate Modification with Aggressive Blood Pressure Control) trial randomized patients into two groups: one with aggressive blood pressure control (<120/80 mm Hg) and another with standard control (<140/90 mm Hg).

    Article Title: Controversies in Hypertension II: The Optimal Target Blood Pressure.
    Article Snippet: Controversies in Hypertension II: The Optimal Target Blood Pressure Edward J. Filippone, MD, Andrew J. Foy, MD, Gerald V. Naccarelli, MD Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Department of Medicine, Penn State University Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center and College of Medicine, Hershey, Penn.

    Article Title: The Role of Risk Factor Modification in Atrial Fibrillation: Outcomes in Catheter Ablation
    Article Snippet: SMAC-AF , 2017 , 184 , 14 , Randomised open-label trial , 57% , Participants assigned to aggressive BP target (<120/80) or standard BP (<140/90) prior to ablation. Primary outcome was >30 s of AF/AT/AFL occurrence , There was no significant difference between the groups (61.4% of aggressive BP control vs. 61.2% in standard treatment group) p = 0.763 [ ] .



    Similar Products

    smac-af  (SMAC Corp)
    90
    SMAC Corp smac-af
    Summaries of studies explored demonstrating impact of risk factor modification on AF ablation outcomes .
    Smac Af, supplied by SMAC Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/smac-af/smac+af/pmc11951490-2-14-5
    Average 90 stars, based on 1 article reviews
    smac-af - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    substrate modification with aggressive blood pressure control: smac-af  (SMAC Corp)
    90
    SMAC Corp substrate modification with aggressive blood pressure control: smac-af
    Summaries of studies explored demonstrating impact of risk factor modification on AF ablation outcomes .
    Substrate Modification With Aggressive Blood Pressure Control: Smac Af, supplied by SMAC Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/smac-af/substrate+modification+with+aggressive+blood+pressure+control++smac+af/pm39152253-130-24-34
    Average 90 stars, based on 1 article reviews
    substrate modification with aggressive blood pressure control: smac-af - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    smac-af [substrate modification with aggressive blood pressure control]  (SMAC Corp)
    90
    SMAC Corp smac-af [substrate modification with aggressive blood pressure control]
    Summaries of studies explored demonstrating impact of risk factor modification on AF ablation outcomes .
    Smac Af [Substrate Modification With Aggressive Blood Pressure Control], supplied by SMAC Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/smac-af/smac+af/pm39210723-1387-31-34
    Average 90 stars, based on 1 article reviews
    smac-af [substrate modification with aggressive blood pressure control] - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    smac-af trial  (SMAC Corp)
    90
    SMAC Corp smac-af trial
    Summaries of studies explored demonstrating impact of risk factor modification on AF ablation outcomes .
    Smac Af Trial, supplied by SMAC Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/smac-af/smac+af+trial/pm38667715-60-4-8
    Average 90 stars, based on 1 article reviews
    smac-af trial - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    smac-af 2017  (SMAC Corp)
    90
    SMAC Corp smac-af 2017
    Summaries of studies explored demonstrating impact of risk factor modification on AF ablation outcomes .
    Smac Af 2017, supplied by SMAC Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/smac-af/smac+af+2017/pmc10867001-40-0-0
    Average 90 stars, based on 1 article reviews
    smac-af 2017 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Summaries of studies explored demonstrating impact of risk factor modification on AF ablation outcomes .

    Journal: Reviews in Cardiovascular Medicine

    Article Title: The Influence of Risk Factor Modification on Atrial Fibrillation Outcomes and Their Impact on the Success of Catheter Ablation

    doi: 10.31083/RCM27175

    Figure Lengend Snippet: Summaries of studies explored demonstrating impact of risk factor modification on AF ablation outcomes .

    Article Snippet: Parkash et al ., 2017 (SMAC-AF) [ ] , AF patients (57% paroxysmal) , Aggressive BP treatment (target < 120 mmHg) vs. standard BP treatment (target < 140 mmHg) , At 12 months: recurrence of AF/atrial tachycardia/atrial flutter not different to control group ( p = 0.763).

    Techniques: Modification, Control